Objective. The purpose of this study was to prospectively assess the performance of real-time tissue elastography (RTE) in the evaluation of breast masses and correlate RTE and American College of Radiology Breast Imaging Reporting and Data System (BI-RADS) assessments with pathologic findings. Methods. Informed consent was obtained from all patients for this Health Insurance Portability and Accountability Act-compliant, Institutional Review Board-approved study. Patients with sonographically visible breast lesions for which a biopsy was recommended were considered potential study participants. Between October 2006 and February 2008, 186 consecutive women with 200 lesions were enrolled. Twelve lesions in 11 patients were excluded, resulting in a study population of 188 lesions in 175 women. After routine B-mode sonographic examination, RTE was performed using a manual freehand compression technique. Study lesions were assigned elasticity scores (ES) based on the system proposed by Itoh et al (Radiology 2006; 239:341-350), where 1 is normal and 5 represents abnormal strain. The lesion size on RTE and B-mode imaging was compared. Results were correlated with BI-RADS assessment and pathologic findings. Results. Pathologic examination revealed 61 of 188 malignancies (32.4%) and 127 of 188 benign lesions (67.6%). Of the malignant lesions, 84% had ES of 5 and 4, whereas 76% of benign lesions had ES of 1 and 2. The sensitivity of RTE was 92.7%, and specificity was 85.8%, with 4 false-negative and 16 false-positive results. Of the biopsy-proven benign BI-RADS 4A lesions, 63 of 76 (82.9%) had ES of 1 and 2, consistent with normal tissue. Conclusions. Real-time tissue elastography may provide additional characterization of breast lesions, improving specificity, particularly for low-suspicion lesions.
lasticity imaging is based on the premise that there is an inherent difference in the pliability of normal versus diseased tissue, and this difference can be measured as strain (displacement or elongation of tissue during manual compression) and displayed in real time during sonographic imaging. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] The breast imagers' interest in elasticity imaging stems from the daily challenge to determine with confidence whether a sonographically visible breast lesion may be benign or malignant. Although characterization of solid breast masses by sonography has improved greatly since the early 1990s, specificity remains low, and to date a large number of breast biopsies result in benign diagnoses. Therefore, any additional sonographic information to improve lesion characterization would help increase specificity. Recently published studies have reported promising results using elasticity imaging, either in comparison with B-mode sonography or in conjunction with the B-mode findings. [13] [14] [15] In addition to overall elasticity findings, several groups have reported that malignant lesions appear larger on real-time tissue elastography (RTE) than on B-mode images 5, [16] [17] [18] [19] ; others have described a color pattern, with blue, green, and red layered in that order (BGR), associated with cystic lesions. 14, 20 With continued investigation and research into this method, the addition of RTE as another imaging characteristic may improve the positive predictive value and specificity of sonography in the evaluation of solid masses in the breast.
The goal of our prospective study was to determine the usefulness of RTE in the evaluation of solid masses or indeterminate breast lesions in a clinical setting with pathology as the reference standard. Specifically, our aim was to establish the correlation of prospectively interpreted RTE results with American College of Radiology Breast Imaging Reporting and Data System (BI-RADS) assessment and pathologic diagnoses of sonographically visible breast masses and to determine whether RTE can improve distinction of benign and malignant lesions, thereby increasing specificity and positive predictive value.
Materials and Methods
This prospective study was approved by the Institutional Review Board and was compliant with the Health Insurance Portability and Accountability Act, and written, signed informed consent was obtained from enrolled patients (Institutional Review Board protocol 2005P-002006).
Patient Selection and Diagnostic Sonographic Examination
Patients presented to our breast imaging center for diagnostic workup for various indications, including palpable breast findings on physical examination and abnormalities detected on mammography or magnetic resonance imaging. All diagnostic breast sonographic examinations were performed on 1 of 3 iU22 machines (Philips Healthcare, Bothell, WA), using linear 5-to 12-or 5-to 17-MHz transducers. Sonographic mass interpretation was based on established criteria first described by Stavros et al 21 in 1995 and included assessment of the shape, margins, internal echo texture, long-axis orientation, and acoustic transmission. Management decisions during the diagnostic workup took into account all available data, including clinical examination findings and magnetic resonance imaging, mammographic, and sonographic features. The decision to biopsy was based on the most suspicious finding. Final BI-RADS assessment categories were assigned using American College of Radiology definitions. 22 At the time of recruitment for this study, our group did not consistently subcategorize BI-RADS 4 lesions into A, B, and C based on low, intermediate, and high suspicion, respectively. For the purpose of this study, these subcategories were retrospectively assigned by the study radiologists during batch review, during which the radiologists were blinded to the pathologic results to minimize bias. This retrospective subcategorization was limited to only those lesions that were prospectively designated BI-RADS 4; BI-RADS 3 and 2 lesions were not reviewed again or reclassified.
All patients with breast lesions for which biopsy was recommended (BI-RADS 4A, 4B, 4C, and 5) were considered potential study patients. Seven patients with final assessment of BI-RADS 2 or 3 also underwent biopsy requested either by the patient or referring physician. Study participants were enrolled on the basis of an agreement to participate, written informed consent, and availability of study staff. The study population thus consisted of consecutive patients with sonographically visible breast masses who were expected to undergo biopsy. Patients who had prior percutaneous or surgical intervention in or adjacent to the area of current clinical concern were excluded. Once study participants were enrolled, RTE was performed either after the diagnostic workup during the same visit or immediately before scheduled sonographically guided core needle biopsy.
Real-time Tissue Elastography
Real-time tissue elastography was performed on a US Food and Drug Administration-approved HI VISION 8500 system (Hitachi Medical Corporation, Twinsburg, OH). This system is capable of conventional B-mode sonography, Doppler sonography, and RTE. Each study lesion was first examined with B-mode sonography using a 50-mm-footprint 12.5-MHz linear array transducer to evaluate the shape, margins, orientation, acoustic transmission, size (longest dimension), and distance from the anterior surface of the mass to the skin. The same transducer was then outfitted with a recommended flat plate, increasing the surface area of the transducer head, providing better skin contact for compression, and minimizing side slip (lateral displacement) for RTE. RTE was performed by 1 of 3 study radiologists (either the principal investigator with 17 years of experience in breast sonography and specifically trained on-site by Hitachi applications staff or 1 of 2 clinical fellows in breast imaging trained by the principal investigator and Hitachi applications staff). The freehand manual compression technique described by Itoh et al 19 was used to generate elastographic images. This was performed by first applying initial light pressure with the transducer, just enough to maintain skin contact. An elasticity image was then created by depressing the breast posteriorly approximately 1 to 2 mm and releasing while maintaining skin contact in a quick vibratory manner, approximately 5 to 7 cycles of depression and release per second, or 300 cycles per minute. A compression scale of 1 to 7 was visible on the screen, and images were obtained only when optimal compression was in the 2 to 4 range. It should be noted that manual compression for RTE actually necessitated first a "letting up" of the usual scanning pressure and then applying light compression. An elasticity color map superimposed on the B-mode images was displayed on the left side of a dual-display image while the corresponding gray scale (B-mode) image was on the right. This allowed continuous real-time visualization for proper transducer positioning. During RTE, both static images and video clips were obtained and stored on the HI VISION 8500 hard drive and transferred to our department's picture archiving and communications system.
The study radiologists reviewed all examinations on the Hitachi machine, measuring the lesion depth on the gray scale image from the skin surface to the superficial lesion margin. The longest lesion dimension was measured on both RTE and the corresponding B-mode image. The B-mode size included the echogenic halo when visible. The RTE size included visible mass margins based on color assignment. Video clips were reviewed, and an elasticity score (ES) for each lesion was assigned by consensus, based on a 5-point scoring system proposed by Itoh et al 19 and summarized here: score 1, normally pliable tissue showing even strain throughout the examined area; score 2, even strain over most of the hypoechoic mass with minimal variability; BGR, layered RTE image with an appearance of blue superficially and then green and red in the deeper portion of a lesion, which has been associated with complicated cysts 14, 20 (for the purpose of this study, these lesions were considered a subcategory of ES 2); score 3, strain at the periphery with sparing of the hypoechoic mass; score 4, minimal strain over the hypoechoic region; and score 5: minimal strain over the entire hypoechoic mass or surrounding area.
This scoring system has been used by other researchers, showing that benign lesions tend to have ES of 1 and 2, whereas most malignant lesions have ES of 4 and 5. An intermediate probability of malignancy is associated with ES 3 lesions.
Biopsy Method and Pathologic Correlation
All percutaneous breast biopsies were performed as large core needle biopsies using a 14-gauge multifire needle (Bard Biopsy Systems, Tempe, AZ) or an 11-gauge vacuum-assisted device (Mammotome; Johnson & Johnson, Cincinnati, OH). Chart reviews provided final pathologic diagnoses.
Statistical Analysis
Sensitivity and specificity summary statistics using 2 × 2 contingency tables were calculated. Hypothesis testing was used to calculate P values for lesion size and depth; receiver operating characteristic analysis was performed for overall accuracy. Table 1 . Of these malignancies, 51 of 61 (83.6%) were prospectively assigned ES 5 (n = 45) and ES 4 (n = 6). The remaining 10 of 61 (16.4%) were prospectively assigned ES 3 (n = 6) and ES 2 (n = 4).
Results

Between
The remaining 127 of 188 lesions (67.6%) were benign in women with a mean age of 42.1 years (range, 21-74 years), mean B-mode size of 10.8 mm (range, 2-35 mm), and RTE size of 11.3 mm (range, 2-37 mm). The average depth was 8 mm (range, 2-26 mm). Benign diagnoses are detailed in Table 2 . Of these 127 benign lesions, 97 (76.4%) were interpreted as ES 1 (n = 22), and ES 2 (n = 75), whereas 30 of 127 (23.6%) were ES 3 (n = 14), ES 4 (n = 11), and ES 5 (n = 5). The average age of patients with malignant lesions was significantly higher than that of those with benign lesions (P < .0001).
Elasticity Score and Pathologic Correlation
Elasticity Score 5 Lesions Fifty of 188 study lesions (26.6%) were interpreted as ES 5 (Figure 1 ), of which 45 (90%) were malignant and 5 (10%) were benign. All ES 5 malignant lesions were invasive carcinomas. Benign lesions included a radial sclerosing lesion (n = 1), a scar (n = 1), nodular adenosis (n = 1), apocrine cysts (n = 1), and a papillary lesion (n = 1).
Elasticity Score 4 Lesions
This score was assigned to 17 of 188 (9.0%) lesions, of which 6 (35.3%) were malignant and 11 (64.7%) were benign. Malignant lesions included invasive ductal carcinoma (IDC; n = 5) and B-cell lymphoma (n = 1). Benign lesions comprised 7 fibroadenomas, 2 cysts, 1 papilloma, and 1 fat necrosis.
Elasticity Score 3 Lesions
There were 20 of 188 (10.6%) lesions characterized as ES 3. Of these, 6 (30%) were malignant and 14 (70%) were benign. Malignant lesions included 4 IDCs (Figure 2 ), 1 invasive tubular carcinoma, and 1 DCIS. Benign lesions included 7 fibroadenomas, 4 cysts, 1 papilloma, 1 sclerosing adenosis, and 1 epithelial hyperplasia.
Elasticity Score 2 Lesions
This score was assigned prospectively to 79 of 188 (42.0%) lesions, of which 75 (94.9%) were benign and 4 (5.1%) were malignant (Tables 1  and 2 ). Of the 4 malignant lesions, 2 were grade 3/3 IDCs measuring greater than 2 cm at 13 and 15 mm in depth, 1 with extensive necrosis ( (Figure 4 ), 4 fibroadenomas ( Figure 5 ), and 1 fat necrosis.
Elasticity Score 1 Lesions
This score was assigned to 22 of 188 (11.7%) lesions; all (100%) were benign ( Figure 6 ).
BI-RADS Category Correlation
Correlation of BI-RADS interpretation with ES is detailed in Tables 3 and 4 .
False-Negative RTE Findings
The 4 study lesions prospectively assigned ES 2 and found to be malignant were interpreted as BI-RADS 5 (n = 2), BI-RADS 4C (n = 1; Figure 4) , and BI-RADS 4B (n = 1). These are detailed in Table 5 .
False-Positive RTE Findings
Five lesions assessed as ES 5 were benign ( Figure  7) , with an average size of 7 mm (range, 5-11 mm) and an average depth of 12 mm (range, 7-15 mm). Of these lesions, 3 were BI-RADS 4C, and 2 were BI-RADS 4B. Pathologic examination showed 1 radial sclerosing lesion, 1 scar, 1 apocrine cyst, 1 nodular adenosis, and 1 papillary lesion. Of the 11 ES 4 lesions that were benign, all were assessed as BI-RADS 4, with an average size of 11 mm (range, 4-27 mm) and an average depth of 12 mm (range, 2-21 mm).
Size Correlation Between RTE and B-mode Sonography
For all benign lesions, the average size on Bmode sonography was 10.8 mm, and the corresponding size on RTE was 11.3 mm, reflecting an average difference of +5.9%. For malignant lesions, the average size was 11.2 mm on B-mode sonography and 15.5 mm on RTE, with an average change of +53.1% ( Figures 1B and 7) . The percentage difference in size between B-mode sonography and RTE of the malignant lesions was significantly greater than that of the benign lesions (P < .0001). 
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Lesion Depth and RTE Accuracy
Lesion depth was measured from the skin surface to the superficial lesion margin. Analysis of our data using various cutoff depths revealed no false-negative findings at depths down to and including 12 mm, and the accuracy of elastography progressively fell with lesions deeper than 12 mm. The lesions that were incorrectly characterized on RTE had a mean depth of 12.8 mm with an SD of 5.4 mm, whereas the lesions for which the RTE accurately predicted the outcome had a mean depth of 8.3 mm with an SD of 4.6 mm. The inaccurately characterized lesions were significantly deeper (P = .0001).
Statistical Analysis
Depending on whether the cutoff included ES 3 lesions, our study showed RTE sensitivity of 84% to 93% and specificity of 76% to 87%. The positive predictive value was up to 76%, whereas the negative predictive value was up to 96%. A detailed analysis is given in Table 6 . The area under the receiver operating characteristic curve (AUC) was calculated using SAS version 9.1 software (SAS Institute Inc, Cary, NC). If we regard ES 4 and 5 as malignant and ES 1, 2, and 3 as benign, the AUC is 0.925. With malignant as ES 4 and 5 and benign as ES 1 and 2 (ES 3 considered indeterminate), the AUC is 0.937. For B-mode sonography, the AUC is 0.963 considering BI-RADS 2 and 3 as benign and BI-RADS 4 and 5 as malignant.
There was no significant difference in the sizes (longest diameter) of lesions accurately characterized on elastography compared with the sizes of lesions with false-positive and -negative findings (P = .1402).
Discussion
Our results corroborate findings reported by other researchers, 14, 15, 18, 19, [23] [24] [25] [26] [27] [28] showing RTE sensitivity of 93% and specificity of 86% (considering ES 1 and 2 as benign and ES 4 and 5 as malignant) compared with B-mode sonography sensitivity of 98% and specificity of 67% (considering BI-RADS 2, 3, and 4A lesions as benign). Although numerous studies have assessed elasticity imaging alone or compared RTE with conventional B-mode sonography, 3 previous studies also reported correlations of elastography with BI-RADS assessment. However, only 1 other study included the low, intermediate, and moderately suspicious subcategories of BI-RADS 4 lesions. 28 In their 2006 report, Thomas et al 13 showed lower sensitivity and higher specificity for elastography compared with BI-RADS and suggested that this was particularly helpful in BI-RADS 3 lesions. In 2007, Tardivon et al 14 reported BI-RADS specificity of 47.5% and RTE specificity of 86.9%. More recently, Cho et al 28 reported BI-RADS specificity of 33% and RTE specificity of 96.4%. If we consider lesions in our study with ES of 1 and 2 as indicative of benign tissue and ES of 4 and 5 as likely representing abnormal or malignant tissue, our results represent specificity of 85.8% for RTE compared with 7.1% based on our BI-RADS classification when category 4 is not subdivided into A, B, and C.
Because a biopsy recommendation is usually based on the most suspicious finding in each case, and our study included no malignancies with benign gray scale features, we do not expect that RTE findings would dissuade us from rec-
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J Ultrasound Med 2010; 29:551-563 ommending biopsy for such lesions. We prospectively categorized 60 of 61 malignancies (98%) as BI-RADS 5 (n = 39), 4C (n = 17), and 4B (n = 4). The 1 remaining case (2%) was interpreted as BI-RADS 4A and ES 4 and was a 4-mm node-negative invasive mucinous carcinoma. We suggest that RTE likely has little clinical utility in further characterizing BI-RADS 5 lesions.
Real-time Tissue Elastography for Breast Lesion Evaluation
In this study 76 of 77 BI-RADS 4A lesions (99%) were benign. Based on RTE, 63 of 76 (83%) were prospectively assigned ES of 1 (n = 15) or 2 (n = 48), indicating benign tissue. Eight of 76 (10.5%) were ES 3, and 5 (7.8%) were ES 4. In our study, all BI-RADS 4A lesions that had ES of 1, 2, and 3 were benign. Similarly, Cho et al 28 found that all BI-RADS 4A lesions with ES of 1 (n = 22) and 3 (n = 8) were histologically benign, but 2 of their 18 BI-RADS 4A lesions with ES of 2 were malignant. Considering 4A lesions as probably benign and therefore grouping them with BI-RADS 3 and 2, our recalculated specificity based on BI-RADS reaches 66.9%. This group of low suspicion (BI-RADS 4A) lesions may be an area where elastography has the most beneficial role, by showing strain characteristics with a high likelihood of benignity and perhaps allowing us to reinterpret some BI-RADS 4A lesions as either BI-RADS 3 or even 2.
There were 34 retrospectively assigned BI-RADS 4B lesions in our study, of which 30 (88%) were benign. In this benign group, 21 of 30 (70%) had ES of 1 or 2. The other 9 of 30 (30%) were ES 3 (n = 2), ES 4 (n = 5), and ES 5 (n = 2). Of the 4 malignant lesions with BI-RADS 4B, 3 (75%) were ES 5, and 1 was ES 2. The ES 2 lesion was a 26-mm IDC at a 13-mm depth. Within this group of 34 lesions, the ES 1 lesion was benign, and 3 of the 4 malignancies were ES 5. The BI-RADS 4B group consisted of the largest number of indeterminate lesions, and RTE also could not reliably predict the pathologic outcome.
Of the lesions assigned BI-RADS 4C in this study, 12 of 29 (41%) were benign. The RTE assessment of these 4C lesions was also unreliable, with ES varying from 2 to 5. These included a wide variety of pathologic types, ranging from normal breast tissue to sclerosing adenosis, apocrine cysts, fibroadenomatous changes, chronic inflammation, and radial sclerosing and papillary lesions. Of the 9 BI-RADS 3 or 2 lesions found to be benign, all had ES of 1 or 2, suggesting that the addition of RTE to B-mode sonography may help increase confidence in interpretation and final assessment.
The ES 3 lesions were a difficult group to categorize with RTE findings, showing minimal strain in the central portion of the lesion and normal strain at the periphery. Although in some previous reports, ES 3 lesions were grouped with ES 2 and 1 lesions as most likely benign, in our study, the lesions we classified as ES 3 had a positive malignancy rate of 30%. With this positive rate, ES 3 lesions could not be deemed likely benign but were indeterminate and underwent biopsy. We performed an extra set of accuracy calculations in which these "truly indeterminate" ES 3 lesions were excluded from the calculations.. Additional experience in assigning this ES may change how it fits with the other scores.
There were 4 of 61 (6.6%) cases with falsenegative RTE findings that were interpreted as ES 2 and found to be malignant. Although some of these cases were done early in our study, when experience was limited, the difference in overall accuracy between the initial and latter halves of our study was not statistically significant. One case included extensive necrosis and was perhaps too large (26 mm) and deep (15 mm) for optimal RTE. Otherwise, even on rereview, we found no apparent common factors to explain this discrepancy. However, BI-RADS assessments of these lesions were 4B, 4C, and 5; thus, histologic analysis would not have been delayed by the RTE findings. A study of 111 nodules by Itoh et al 19 included false-negative elastographic scores in cases of DCIS and invasive nonscirrhous carcinomas, whereas Giuseppetti et al 23 reported false-negative findings including invasive carcinoma with mixed ductal and lobular features, lobular carcinoma, and ductal carcinoma. Our cases with false-negative findings (ES 2) are detailed in Table 4 and included 3 IDCs and 1 invasive lobular carcinoma (mixed ductal and lobular), grades 2 and 3. To minimize falsenegative findings, Tardivon et al 14 recommended in a 2007 report that all ES 3 lesions undergo biopsy because this raises the sensitivity while still keeping specificity at a level above that of Bmode sonography. We found that considering ES 3 cases under a separate (indeterminate) catego-ry improved our sensitivity from 84% (if they were considered benign) to 93%. However, we would suggest that the decision to biopsy such lesions should be aided by combined gray scale characterization and RTE findings.
Our cases with false-positive RTE findings (5 ES 5 and 11 ES 4 lesions) were also suspicious on Bmode sonography and interpreted as BI-RADS 4 (Table 4) . Although some of these were pathologic entities for which abnormal strain or elasticity is not surprising (radial sclerosing lesion or scar), others were variable. We found that the cases with false-positive and -negative findings were located deeper (farther from the scanning surface) than those that were accurately characterized on elastography. We note the discussion point by Thomas et al 24 that both of the observers in their study concluded independently that lesions located deeper than 1 cm cannot be evaluated adequately by elastography. Analysis of our data using various cutoff depths revealed no false-negative findings at depths of 12 mm or less, and the accuracy of elastography progressively fell with lesions greater than 12 mm deep, suggesting this as a cutoff depth to be considered.
An elastographic color map with BGR layering has been associated with complicated cysts. 14, 21 In our study, we saw this appearance in 10 of 188 lesions (5.3%), including 5 cysts (50%), 4 fibroadenomas, and 1 fat necrosis. This is believed to be an artifactual color assignment related to the paucity of echoes affecting calculation of strain. Histologic review of the 4 fibroadenomas revealed 3 with myxoid stroma and 1 with dense stroma. The significance of this finding requires further evaluation in larger series. Of note, only 5 of 23 cystic lesions in our study showed BGR on RTE.
Our results corroborate other reports showing that whereas malignant lesions appear larger on RTE compared with B-mode sonography (+53.1%), benign lesions remain essentially unchanged (+5.9%), making this size change a feature that may, in otherwise equivocal cases, support a decision to biopsy. If validated in larger series, this feature may prove to be reliable and therefore perhaps the most effective and useful RTE characteristic.
Our study had several shortcomings. First, we recognize that as experienced breast imagers, when analyzing B-mode and RTE images placed side by side to assign elastography scores, it is impossible to avoid bias based on the gray scale appearance of a lesion. Second, our study did not assess interobserver or intraobserver variability with regard to performing and interpreting RTE. This issue may prove challenging, especially in a practice setting with different levels of experience. Performance of RTE was not always straightforward because it depends on multiple factors such as breast size, density, depth, and proximity of a lesion to the nipple/areola, making it difficult to achieve consistently optimal image quality for all cases. Previous reports showed variable results. Thomas et al 24 had good κ values (0.86) between observers, whereas Regner et al 25 showed mixed levels of agreement. These RTE limitations need to be addressed in larger studies, and methods can be developed to decrease operator dependence, including more quantitative elasticity assessment methods and further improve RTE sensitivity and specificity.
In conclusion, our results are concordant with other researchers' findings, and if validated by larger studies, RTE combined with B-mode characterization may potentially increase our level of confidence regarding final assessment and help us avoid biopsy recommendations for lesions with a very high probability of being benign.
